Shield Therapeutics Focuses on Cash Management to Reach Breakeven

Shield Therapeutics, a pharmaceutical company specializing in iron deficiency treatments, is actively managing its cash flow to achieve breakeven by the second half of 2025. The company's flagship product, ACCRUFeR®, an oral drug targeting iron deficiency, has gained increased physician awareness since its US launch in July 2021. This has bolstered sales momentum. However, Shield is not complacent. It extended its working capital facility from $10 million to $15 million and issued new shares worth $10 million to strategic partner AOP. These measures aim to ensure financial stability and support its journey to cashflow breakeven. The company's proactive financial strategy highlights its commitment to navigating market challenges effectively.